Advancing FDA-Cleared Phase IIa Parkinson’s Program Targeting NeuroinflammationDual-Path Strategy Combines Clinical Development with ...
Repayment Commencement Deferred to April 1, 2026 Core Economic Terms of $6.0 Million Financing Remain Unchanged JUPITER, FL, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS ...
Jupiter executives are expected to provide updates on the Company’s clinical progress, commercial strategy, and long-term objectives. Management intends to discuss advancement of the Phase IIa ...
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results